SLC2A1 and soft tissue sarcoma: In soft tissue sarcomas, a glycolytic CAF subset drives immunosuppression through GLUT1-mediated metabolic competition and CXCL16-dependent CD8+ T cell exclusion, spurring the development of GLUT1 inhibitors (Broz et al., 2024).